Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: October 6, 2022

Details for Patent: 9,012,469

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 9,012,469 protect, and when does it expire?

Patent 9,012,469 protects MOVANTIK and is included in one NDA.

This patent has forty-five patent family members in thirty-eight countries.

Summary for Patent: 9,012,469
Title:Crystalline naloxol-peg conjugate
Abstract: Naloxol-polyethlyene glycol conjugates of the formula: are provided in oxalate or phosphate salt forms including crystalline forms. Methods of preparing the salt forms and pharmaceutical compositions comprising the salt forms are also provided.
Inventor(s): .ANG.slund; Bengt Leonard (Alderley Park, GB), Aurell; Carl-Johan (Alderley Park, GB), Bohlin; Martin Hans (Alderley Park, GB), Healy; Eric Thomas (Waltham, MA), Jensen; David Richard (Waltham, MA), Jonaitis; David Thomas (Waltham, MA), Parent; Stephan (Waltham, MA), Sebhatu; Tesfai (Alderley Park, GB), Ymen; Bo Ingvar (Alderley Park, GB)
Assignee: AstraZeneca AB (Sodertalje, SE) Nektar Therapeutics (San Francisco, CA)
Application Number:13/823,953
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,012,469
Patent Claim Types:
see list of patent claims
Compound; Use; Formulation; Composition; Dosage form;

Drugs Protected by US Patent 9,012,469

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Redhill MOVANTIK naloxegol oxalate TABLET;ORAL 204760-001 Sep 16, 2014 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Redhill MOVANTIK naloxegol oxalate TABLET;ORAL 204760-002 Sep 16, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,012,469

PCT Information
PCT FiledSeptember 29, 2011PCT Application Number:PCT/SE2011/051161
PCT Publication Date:April 05, 2012PCT Publication Number: WO2012/044243

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.